PTCHF
PureTech Health plc
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
1.57
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.57
Prev close
1.57
Day high
1.80
Day low
1.80
Volume
4.86K
Market cap
$380.95M
P/E (TTM)
—
52W range
1.53 – 1.92
Day trading desk
Gap from prior close
-0.00%
Prior close 1.57
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
1.57 – 1.57
Position in range
—
—
ATR (14D)
0.00
0.16% of price
Prior day high
1.57
PDH
Prior day low
1.57
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 951
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
-2.00%
-5.7%
3M
-5.15%
-8.2%
6M
-7.83%
-18.9%
YTD
-8.21%
-20.5%
1Y
-12.57%
-32.6%
3Y
-33.40%
-107.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PTCHF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
24.46M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | Elenko (Eric) |
— | 98.13K | — | Direct |
| Aug 17, 26 | Inbar (Michael) |
— | 20.02K | — | Direct |
| Aug 17, 26 | PureTech Health PLC |
— | 804.62K | — | Direct |
| Aug 17, 26 | Sherwood (Charles H Jr) |
— | 41.10K | — | Direct |
| Jul 31, 26 | PureTech Health PLC |
— | 0 | — | Direct |
| Jul 29, 26 | PureTech Health PLC |
— | 477.73K | — | Direct |
| Jul 29, 26 | Langer (Robert S Jr.) |
BUY | 93.94K | $1.22K | Direct |
| Jul 29, 26 | Mazumdar-Shaw (Kiran) |
BUY | 93.94K | $1.22K | Direct |
| Jul 29, 26 | Holcomb (Michele A. M. Ph.D.) |
BUY | 93.94K | $1.22K | Direct |
| Jul 29, 26 | LaMattina (John L) |
BUY | 93.94K | $1.22K | Direct |
| Jul 29, 26 | Barber-lui (Sharon) |
BUY | 93.94K | $1.22K | Direct |
| Jul 14, 26 | Elenko (Eric) |
— | 56.73K | — | Direct |
| Jul 14, 26 | Inbar (Michael) |
— | 30.25K | — | Direct |
| Jul 14, 26 | PureTech Health PLC |
— | 479.11K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Baillie Gifford & Co |
— | 8.64M | Annual Return |
Briarwood Chase Management L.L.C. |
— | 12.40M | Increase |
Citigroup Global Markets, Ltd. |
— | 14.75M | Increase |
FIL Limited |
— | 8.19M | Annual Return |
Invesco, Ltd. |
— | 41.02M | Annual Return |
Lansdowne Partners Ltd Partnership |
— | 13.90M | Annual Return |
PureTech Health PLC |
— | 12.75M | Decrease |
Recordati Sa |
— | 9.57M | Annual Return |
Tang Capital Partners L P |
— | 12.22M | Increase |
Zohar (Daphne) |
— | 7.73M | Annual Return |
Fundamentals
Market cap$380.95M
Enterprise value$288.97M
Revenue (TTM)$4.66M
Gross profit$-51.80M
EBITDA$-96.83M
Net income$-109.74M
EPS (TTM)$-0.46
Free cash flow$-89.99M
Total cash$288.72M
Total debt$203.26M
Book value / share$1.29
Shares outstanding243.42M
Float156.80M
Short % of float—
Dividend yield—
Beta (5Y)0.77
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.21
EV / revenue62.02
EV / EBITDA-2.98
Gross margin0.00%
Operating margin-1797.79%
Profit margin0.00%
Return on equity-30.85%
Return on assets-10.82%
Debt / equity66.49
Current ratio6.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Operating revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Research & development | $45.74M | $54.28M | $73.73M | $111.29M | -15.7% |
| Selling, general & admin | $20.65M | $27.49M | $25.18M | $31.60M | -24.9% |
| Total operating expense | $103.18M | $140.41M | $146.95M | $199.90M | -26.5% |
| Operating income | -$98.53M | -$136.09M | -$146.20M | -$197.81M | +27.6% |
| Net interest income | -$32.73M | $12.63M | $2.52M | $1.85M | -359.1% |
| Pre-tax income | -$110.93M | $23.77M | -$36.10M | -$92.78M | -566.6% |
| Tax provision | -$842.00K | -$4.01M | $30.52M | -$55.72M | +79.0% |
| Net income | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Net income to common | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Basic EPS | -0.46 | 0.21 | -0.24 | -0.18 | -319.0% |
| Diluted EPS | -0.46 | 0.21 | -0.24 | -0.18 | -319.0% |
| EBIT | -$65.15M | $33.81M | -$22.61M | -$88.83M | -292.7% |
| EBITDA | -$61.80M | $37.38M | -$17.68M | -$79.94M | -265.3% |
| Basic shares | 240.79M | 254.46M | 276.30M | 284.76M | -5.4% |
| Diluted shares | 240.79M | 256.03M | 276.30M | 284.76M | -6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $252.47M | $280.64M | $191.08M | $149.87M | — | -10.0% |
| Cash & short-term investments | $277.30M | $367.31M | $327.14M | $350.10M | — | -24.5% |
| Accounts receivable | $1.76M | $1.52M | $2.38M | $11.87M | — | +15.5% |
| Total current assets | $305.02M | $386.26M | $347.20M | $386.19M | — | -21.0% |
| Property, plant & equipment | $11.50M | $15.13M | $19.36M | $37.24M | — | -24.0% |
| Goodwill & intangibles | $601.00K | $601.00K | $906.00K | $831.00K | — | 0.0% |
| Total assets | $534.71M | $602.63M | $693.97M | $702.65M | — | -11.3% |
| Total current liabilities | $46.31M | $41.39M | $51.37M | $96.89M | — | +11.9% |
| Current debt | $4.92M | $4.11M | $3.70M | $7.50M | — | +19.6% |
| Long-term debt | — | — | $0 | $10.24M | $14.26M | — |
| Total debt | $19.59M | $22.36M | $25.34M | $46.87M | — | -12.4% |
| Total liabilities | $229.03M | $194.70M | $235.74M | $155.06M | — | +17.6% |
| Retained earnings | -$77.23M | $32.49M | $83.82M | $149.52M | — | -337.7% |
| Shareholder equity | $312.07M | $414.71M | $464.07M | $542.22M | — | -24.7% |
| Working capital | $258.71M | $344.87M | $295.83M | $289.31M | — | -25.0% |
| Net tangible assets | $311.47M | $414.11M | $463.16M | $541.39M | — | -24.8% |
| Shares issued | 257.93M | 257.93M | 289.47M | 289.16M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$110.08M | $27.78M | -$66.63M | -$37.06M | -496.2% |
| Depreciation & amortisation | $3.35M | $3.57M | $4.93M | $8.89M | -6.2% |
| Stock-based compensation | $8.22M | $22.85M | $4.42M | $14.70M | -64.0% |
| Change in working capital | -$3.12M | -$10.24M | $17.52M | $15.92M | +69.5% |
| Operating cash flow | -$85.13M | -$134.37M | -$105.92M | -$178.79M | +36.6% |
| Capital expenditure | -$6.00K | -$11.00K | -$245.00K | -$2.18M | +45.5% |
| Investing cash flow | $63.29M | $240.89M | $68.99M | -$107.22M | -73.7% |
| Share buybacks | -$2.05M | -$107.56M | -$19.65M | -$26.49M | +98.1% |
| Financing cash flow | -$6.33M | -$16.96M | $78.14M | -$29.83M | +62.7% |
| Free cash flow | -$85.14M | -$134.38M | -$106.16M | -$180.97M | +36.6% |
| End cash position | $252.47M | $280.64M | $191.08M | $149.87M | -10.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $252.47M | $260.60M | $280.64M | -3.1% |
| Cash & short-term investments | $277.30M | $321.55M | $367.31M | -13.8% |
| Accounts receivable | $1.76M | $2.49M | $1.52M | -29.3% |
| Total current assets | $305.02M | $344.39M | $386.26M | -11.4% |
| Property, plant & equipment | $11.50M | $13.31M | $15.13M | -13.6% |
| Goodwill & intangibles | $601.00K | $601.00K | $601.00K | 0.0% |
| Total assets | $534.71M | $553.24M | $602.63M | -3.3% |
| Total current liabilities | $46.31M | $40.58M | $41.39M | +14.1% |
| Current debt | $4.92M | $4.50M | $4.11M | +9.3% |
| Total debt | $19.59M | $20.92M | $22.36M | -6.4% |
| Total liabilities | $229.03M | $184.22M | $194.70M | +24.3% |
| Retained earnings | -$77.23M | -$12.10M | $32.49M | -538.4% |
| Shareholder equity | $312.07M | $375.98M | $414.71M | -17.0% |
| Working capital | $258.71M | $303.81M | $344.87M | -14.8% |
| Net tangible assets | $311.47M | $375.37M | $414.11M | -17.0% |
| Shares issued | 257.93M | 257.93M | 257.93M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $7.10M | +52.4% |
| Next year | — | — | $13.47M | +89.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders10.05%
Held by institutions52.19%
Institutions holding29
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.57
-0.00% from price
SMA 20
1.55
+0.90% from price
SMA 50
1.61
-2.75% from price
SMA 100
1.67
-6.47% from price
SMA 200
1.68
-6.80% from price
EMA 12
1.56
+0.13% from price
EMA 26
1.57
-0.60% from price
EMA 50
1.61
-2.59% from price
RSI (14)
38.7
Neutral
MACD (12,26,9)
-0.01
Hist 0.01
ATR (14)
0.00
0.16% of price
Realised vol 30D
14.0%
Annualised
Bollinger upper
1.59
20, 2σ
Bollinger lower
1.52
20, 2σ
50 / 200 cross
Death
1.61 vs 1.68
Trend bias
Below 200
-6.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.01
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
14.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-20.3%
Peak to trough
Max drawdown 5Y
-74.9%
Peak to trough
ATR 14
0.00
0.16% of price
Beta (reported)
0.77
5Y monthly, from filing
SEC filings
Offering Registrations
F-6 POS · 2026-05-22
Notice of termination by a Foreign Private Issuer of a class of equity securities under Section 12(b)
15F-12B · 2026-05-21
Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange
25 · 2026-05-11
Corporate Changes & Voting Matters
6-K · 2026-05-01
Corporate Changes & Voting Matters
6-K · 2026-04-29
Corporate Changes & Voting Matters
6-K · 2025-12-18
Corporate Changes & Voting Matters
6-K · 2025-12-10
Corporate Changes & Voting Matters
6-K · 2025-08-28
Headlines
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 41d ago
Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial
Clinical Trials Arena · 51d ago
A PureTech startup banks $180M for a new IPF drug
BioPharma Dive · 52d ago
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 52d ago
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 52d ago
PureTech Health: Results of Annual General Meeting
Business Wire · 74d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Business Wire · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.